Clover Health (US.CLOV)
Capital Allocation Audit · Period: 2019 – 2026
Key Metrics
US.CLOV · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 99.2% | → |
| ROE | 8.1% | ↑ |
| Cash Conversion | 394.7% | → |
| D/E Ratio | 0.00 | ↓ |
| Gross Margin | 21.3% | ↓ |
US.CLOV (Clover Health) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 99.2% → ROE 8.1% ↑ Cash Conversion 394.7% → D/E Ratio 0.00 ↓ Gross Margin 21.3% ↓
Key Metrics
US.CLOV (Clover Health) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 99.2% →ROE 8.1% ↑Cash Conversion 394.7% →D/E Ratio 0.00 ↓Gross Margin 21.3% ↓Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies